Xenon Pharmaceuticals Inc. XENE
42.10 USD +0.71 (+1.72%)
At closeNov 12, 2026, 4:01 AM EST
42.09 -0.01 -0.02%
Pre-market · Nov 12, 4:01 AM ET
40.88 Day range 42.17
33.38 52-week range 72.66
- YTD
- -6.07%
- 1 year
- +5.46%
News
seekingalpha.com Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript
marketbeat.com Xenon Pharmaceuticals Q3 Earnings Call Highlights Xenon Pharmaceuticals NASDAQ: XENE expects pivotal depression study results in December, earlier than previously projected, while preparing for a potential U.S. launch of its lead epilepsy drug and…
benzinga.com Xenon Pharmaceuticals Q3 2026 Earnings Call Transcript Xenon Pharmaceuticals (NASDAQ:XENE) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Xenon Pharmaceuticals Q3 EPS $(1.11) Beats $(1.13) Estimate Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.13) by 1.77 percent. This is a 3.48 percent increase over losses of…
globenewswire.com Xenon Reports Q3 2026 Financial Results and Provides Business Update New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and…
benzinga.com Xenon Pharmaceuticals Announces Its XEN1701 Surpasses Target Profile; Data Presented During International Association For The Study Of Pain 2026 World Congress On Pain Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for…
benzinga.com Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call Xenon Pharmaceuticals (NASDAQ:XENE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is…